PEN – Penumbra, Inc.
Float Short %
4.21
Margin Of Safety %
-23
Put/Call OI Ratio
0.58
EPS Next Q Diff
0.11
EPS Last/This Y
3.41
EPS This/Next Y
1.28
Price
339.3
Target Price
361.07
Analyst Recom
2.7
Performance Q
22.03
Upside
-56.9%
Beta
0.81
Ticker: PEN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | PEN | 358.81 | 0.60 | 2.58 | 3850 |
| 2026-01-26 | PEN | 358.88 | 0.64 | 2.40 | 3929 |
| 2026-01-27 | PEN | 359.27 | 0.65 | 6.25 | 3948 |
| 2026-01-28 | PEN | 359.18 | 0.66 | 5.60 | 3971 |
| 2026-01-29 | PEN | 356.98 | 0.66 | 21.00 | 3980 |
| 2026-01-30 | PEN | 358.37 | 0.69 | 0.00 | 4043 |
| 2026-02-02 | PEN | 356.98 | 0.69 | 14.00 | 4055 |
| 2026-02-04 | PEN | 340 | 0.70 | 4.33 | 4106 |
| 2026-02-05 | PEN | 341.93 | 0.71 | 0.03 | 4285 |
| 2026-02-06 | PEN | 340.79 | 0.51 | 2.63 | 5319 |
| 2026-02-09 | PEN | 339 | 0.52 | 2.63 | 5361 |
| 2026-02-10 | PEN | 339.09 | 0.53 | 1.03 | 5432 |
| 2026-02-11 | PEN | 338.31 | 0.54 | 1.30 | 5537 |
| 2026-02-12 | PEN | 338.78 | 0.56 | 1.95 | 5756 |
| 2026-02-13 | PEN | 340.5 | 0.57 | 5.07 | 5796 |
| 2026-02-18 | PEN | 341.11 | 0.58 | 0.21 | 5869 |
| 2026-02-19 | PEN | 340.61 | 0.58 | 0.65 | 5870 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | PEN | 359.21 | 14.7 | 55.9 | 3.77 |
| 2026-01-26 | PEN | 358.87 | 14.7 | 55.2 | 3.77 |
| 2026-01-27 | PEN | 359.12 | 14.7 | 55.5 | 3.77 |
| 2026-01-28 | PEN | 359.55 | 14.7 | 55.6 | 3.77 |
| 2026-01-29 | PEN | 356.93 | 14.7 | 54.0 | 3.77 |
| 2026-01-30 | PEN | 358.35 | 14.7 | 56.4 | 3.77 |
| 2026-02-02 | PEN | 356.97 | 14.7 | 54.6 | 3.77 |
| 2026-02-03 | PEN | 356.00 | 14.7 | 54.8 | 3.77 |
| 2026-02-04 | PEN | 339.92 | 14.7 | 44.3 | 3.77 |
| 2026-02-05 | PEN | 342.00 | 14.7 | 57.0 | 3.77 |
| 2026-02-06 | PEN | 340.89 | 14.7 | 54.6 | 3.77 |
| 2026-02-09 | PEN | 339.19 | 14.7 | 54.1 | 3.77 |
| 2026-02-10 | PEN | 338.99 | 14.7 | 55.4 | 3.77 |
| 2026-02-11 | PEN | 338.30 | 14.7 | 55.0 | 3.77 |
| 2026-02-12 | PEN | 338.78 | 14.7 | 55.8 | 3.77 |
| 2026-02-13 | PEN | 339.54 | 14.7 | 56.0 | 3.77 |
| 2026-02-17 | PEN | 341.11 | 14.7 | 56.8 | 3.77 |
| 2026-02-18 | PEN | 341.13 | 14.7 | 55.5 | 3.77 |
| 2026-02-19 | PEN | 340.64 | 14.7 | - | 3.77 |
| 2026-02-20 | PEN | 339.30 | 14.7 | - | 3.77 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | PEN | -8.66 | 2.65 | 4.50 |
| 2026-01-26 | PEN | -7.53 | 2.50 | 4.50 |
| 2026-01-27 | PEN | -7.53 | 2.50 | 4.50 |
| 2026-01-28 | PEN | -7.53 | 2.50 | 4.53 |
| 2026-01-29 | PEN | -7.53 | 2.50 | 4.53 |
| 2026-01-30 | PEN | -7.53 | 2.50 | 4.53 |
| 2026-02-02 | PEN | -7.53 | 2.44 | 4.53 |
| 2026-02-03 | PEN | -7.53 | 2.44 | 4.53 |
| 2026-02-04 | PEN | -7.53 | 2.44 | 4.53 |
| 2026-02-05 | PEN | -7.53 | 2.44 | 4.53 |
| 2026-02-06 | PEN | -7.53 | 2.44 | 4.53 |
| 2026-02-09 | PEN | -6.38 | 1.84 | 4.53 |
| 2026-02-10 | PEN | -6.38 | 1.84 | 4.53 |
| 2026-02-11 | PEN | -6.38 | 1.84 | 4.21 |
| 2026-02-12 | PEN | -6.38 | 1.84 | 4.21 |
| 2026-02-13 | PEN | -6.38 | 1.84 | 4.21 |
| 2026-02-17 | PEN | -5.28 | -6.58 | 4.21 |
| 2026-02-18 | PEN | -5.28 | -6.58 | 4.21 |
| 2026-02-19 | PEN | -5.28 | -6.58 | 4.21 |
| 2026-02-20 | PEN | -5.28 | -6.58 | 4.21 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.97
Avg. EPS Est. Current Quarter
1.09
Avg. EPS Est. Next Quarter
1.08
Insider Transactions
-5.28
Institutional Transactions
-6.58
Beta
0.81
Average Sales Estimate Current Quarter
361
Average Sales Estimate Next Quarter
370
Fair Value
261.54
Quality Score
95
Growth Score
84
Sentiment Score
69
Actual DrawDown %
6.4
Max Drawdown 5-Year %
-62.6
Target Price
361.07
P/E
81.1
Forward P/E
67.15
PEG
1.57
P/S
9.98
P/B
9.78
P/Free Cash Flow
87.23
EPS
4.18
Average EPS Est. Cur. Y
3.77
EPS Next Y. (Est.)
5.05
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
12.3
Relative Volume
0.65
Return on Equity vs Sector %
-16.9
Return on Equity vs Industry %
-5.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Penumbra, Inc.Sector: Healthcare
Industry: Medical Devices
Employees: 4500
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
stock quote shares PEN – Penumbra, Inc. Stock Price stock today
news today PEN – Penumbra, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PEN – Penumbra, Inc. yahoo finance google finance
stock history PEN – Penumbra, Inc. invest stock market
stock prices PEN premarket after hours
ticker PEN fair value insiders trading